Venezuelan equine encephalitis replicon particles can induce rapid protection against foot-and-mouth disease virus

Journal of Virology

Volumn 87, Issue 10, 2013, Pages 5447-5460

  Segundo, Fayna Diaz San ^a   Dias, Camila C A ^a,b   Moraes, Mauro P ^c,e   Weiss, Marcelo ^a,b   Perez Martin, Eva ^a,b   Owens, Gary ^d,f   Custer, Max ^d,g   Kamrud, Kurt ^a,h   de los Santos, Teresa ^a   Grubman, Marvin J ^a  

^a PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

^b OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d AlphaVax Inc   (United States)

^e Ceva Biomune   (United States)

^f Liquidia Technologies   (United States)

^g NOVARTIS   (United States)

^h Harrisvaccines   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GREEN FLUORESCENT PROTEIN; INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FOOT AND MOUTH DISEASE VIRUS; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE NUMBER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPLICON; UNINDEXED SEQUENCE; UPREGULATION; VENEZUELAN EQUINE ENCEPHALITIS; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIREMIA; VIRUS GENE; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; GENETIC THERAPY; GENETIC VECTORS; INTERFERON-ALPHA; MICE; MICE, INBRED C57BL; SURVIVAL ANALYSIS;

EID: 84877346061     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03462-12     Document Type: Article

References (41)

1. Grubman MJ, Baxt B. 2004. Foot-and-mouth disease. Clin. Microbiol. Rev. 17:465- 493.
2. Domingo E, Escarmís C, Baranowski E, Ruiz-Jarabo CM, Carrillo E, Nunez JI, Sobrino F. 2003. Evolution of foot-and-mouth disease virus. Virus Res. 91:47- 63.
3. Golde WT, Pacheco JM, Duque H, Doel T, Penfold B, Ferman GS, Gregg DR, Rodriguez LL. 2005. Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: use in emergency outbreak response. Vaccine 23: 5775-5782.
4. Moraes MP, Chinsangaram J, Brum MCS, Grubman MJ. 2003. Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. Vaccine 22:268 -279.
5. Pacheco JM, Brum MCS, Moraes MP, Golde WT, Grubman MJ. 2005. Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus vectored FMDV subunit vaccine. Virology 337:205-209.
6. Chinsangaram J, Koster M, Grubman MJ. 2001. Inhibition of L-deleted foot-and-mouth disease virus replication by alpha/beta interferon involves double-stranded RNA-dependent protein kinase. J. Virol. 75: 5498-5503.
7. Moraes MP, de los Santos T, Koster M, Turecek T, Wang H, Andreyev VG, Grubman MJ. 2007. Enhanced antiviral activity against foot-andmouth disease virus by a combination of type I and II porcine interferons. J. Virol. 81:7124 -7135.
8. Díaz-San Segundo F, Weiss M, Perez-Martín E, Koster MJ, Zhu J, Grubman MJ, de los Santos T. 2011. Antiviral activity of bovine type III interferon against foot-and-mouth disease virus. Virology 413:283-292.
9. Chinsangaram J, Moraes MP, Koster M, Grubman MJ. 2003. Novel viral disease control strategy: adenovirus expressing alpha interferon rapidly protects swine from foot-and-mouth disease. J. Virol. 77:1621-1625.
10. Dias CCA, Moraes MP, Diaz-San Segundo F, de los Santos T, Grubman MJ. 2011. Porcine type I interferon rapidly protects swine against challenge with multiple serotypes of foot-and-mouth disease virus. J. Interferon Cytokine Res. 31:227-236.
11. Wu Q, Brum MCS, Caron L, Koster M, Grubman MJ. 2003. Adenovirus- mediated type I interferon expression delays and reduces disease signs in cattle challenged with foot-and-mouth disease virus. J. Interferon Cytokine Res. 23:359 -368.
12. Perez-Martin E, Weiss M, Diaz-San Segundo F, Pacheco JM, Arzt J, Grubman MJ, de los Santos T. 2012. Bovine type III interferon significantly delays and reduces severity of foot-and-mouth disease in cattle. J. Virol. 86:4477- 4487.
13. Medzhitov R, Janeway CA, Jr. 1998. Innate immune recognition and control of adaptive immune responses. Semin. Immunol. 10:351-353.
14. Honda K, Taniguchi T. 2006. IRFs: master regulators of signaling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6:644-658.
15. Kawai T, Akira S. 2011. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34:637- 650.
16. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE. 1997. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389-401.
17. Lee JS, Hadjipanayis AG, Welkos SL. 2003. Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge. Infect. Immun. 71:1491-1496.
18. Hooper JW, Ferro AM, Golden JW, Silvera P, Dudek J, Alterson K, Custer M, Rivers B, Morris J, Owens G, Smith JF, Kamrud KI. 2009. Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine 28:494 -511.
19. Konopka JL, Penalva LO, Thompson JM, White LJ, Beard CW, Keene JD, Johnston RE. 2007. A two-phase innate host response to alphavirus infection identified by mRNP-tagging in vivo. PLoS Pathog. 3:e199. doi: 10.1371/journal.ppat.0030199.
20. Konopka JL, Thompson JM, Whitmore AC, Webb DL, Johnston RE. 2009. Acute infection with Venezuelan equine encephalitis virus replicon particles catalyzes a systemic antiviral state and protects from lethal virus challenge. J. Virol. 83:12432-12442.
21. Swaney LM. 1988. A continuous bovine kidney cell line for routine assays of foot-and-mouth disease virus. Vet. Microbiol. 18:1-14.
22. Graham F, Prevec L. 1991. Manipulation of adenovirus vectors, p 109- 128. In Murray EJ (ed), Gene transfer and expression protocols. Methods in molecular biology, vol 7. Humana Press, Clifton, NJ.
23. Kinney RM, Johnson BJ, Welch JB, Tsuchiya KR, Trent DW. 1989. The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83. Virology 170:19 -38.
24. Bernstein DI, Reap EA, Katen K, Watson A, Smith K, Norberg P, Olmsted RA, Hoeper A, Morris J, Negri S, Maughan MF, Chulay JD. 2009. Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28:484-493.
25. Kamrud KI, Custer M, Dudek JM, Owens G, Alterson KD, Lee JS, Groebner JL, Smith JF. 2007. Alphavirus replicon approach to promoterless analysis of IRES elements. Virology 360:376 -387.
26. Moraes MP, Mayr GA, Grubman MJ. 2001. pAd5-Blue: an easy to use, efficient, direct ligation system for engineering recombinant adenovirus constructs. Biotechniques 31:1050 -1056.
27. Moraes MP, Mayr GA, Mason PW, Grubman MJ. 2002. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 20:1631-1639.
28. de los Santos T, de Avila Botton S, Weiblen R, Grubman MJ. 2006. The leader proteinase of foot-and-mouth disease virus inhibits the induction of beta interferon mRNA and blocks the host innate immune response. J. Virol. 80:1906 -1914.
29. Dias CC, Moraes MP, Weiss M, Diaz-San Segundo F, Perez-Martin E, Salazar AM, de los Santos T, Grubman MJ. 2012. Novel antiviral therapeutics to control foot-and-mouth disease. J. Interferon Cytokine Res. 32:462- 473.
30. Applied Biosystems. 1997. User bulletin 2. ABI Prism 7700 sequence detection system: relative quantification of gene expression (P/N 4303859). Applied Biosystems, Foster City, CA.
31. Georgel P, Jiang Z, Kunz S, Janssen E, Mols J, Hoebe K, Bahram S, Oldstone MBS, Beutler B. 2007. Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. Virology 362:304 -313.
32. Salguero FJ, Sanchez-Martin MA, Diaz-San Segundo F, de Avila A, Sevilla N. 2005. Foot-and-mouth disease virus (FMDV) causes an acute disease that can be lethal for adult laboratory mice. Virology 332:384 -396.
33. Diaz-San Segundo F, Moraes MP, de los Santos T, Dias CCA, Grubman MJ. 2010. Interferon-induced protection against foot-and-mouth disease virus correlates with enhanced tissue specific innate immune cell infiltration and interferon stimulated gene expression. J. Virol. 84:2063-2077.
34. Abe T, Takahashi H, Hamazaki H, Miyano-Kurosaki N, Matsuura Y, Takaku H. 2003. Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice. J. Immunol. 17:1133-1139.
35. Molinari P, Garcia-Nunez S, Gravisaco MJ, Carrillo E, Berinstein A, Taboga O. 2010. Baculovirus treatment fully protects mice against a lethal challenge of FMDV. Antiviral Res. 87:276 -279.
36. Hartman ZC, Black EP, Amalfitano A. 2007. Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells. Virology 358:357-372.
37. Muruve DA. 2004. The innate immune response to adenovirus vectors. Hum. Gene Ther. 15:1157-1166.
38. Muruve DA, Barnes MJ, Stillman IE, Libermann TA. 1999. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10:965- 976.
39. Zhang Y, Chirmule N, Gao GP, Qian R, Croyle M, Joshi B, Tazelaar J, Wilson JM. 2001. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 3:697- 707.
40. Marie I, Durbin JE, Levy DE. 1998. Differential viral induction of distinct interferonα genes by positive feedback through interferon regulatory factor- 7. EMBO J. 17:6660-6669.
41. Taub DD, Sayers TJ, Carter CR, Ortaldo JR. 1995. α and β chemokines induce NK cell migration and enhance NK-mediated cytolysis. J. Immunol. 155:3877-3888.